Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients (PIFNPK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00085917|
Recruitment Status : Completed
First Posted : June 17, 2004
Results First Posted : June 15, 2011
Last Update Posted : June 27, 2011
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Drug: Double dose pegylated interferon with weight based Ribavirin
Drug: standard dose pegylated interferon alfa -2a and ribavirin
|Recruitment Details||Recruitment period was over a period of 3 yrs from 2004 - 2007. Participants were recruited and screened through the OP8 clinic of the NIAID.|
There were no significant events or approaches following participant enrollment prior to group assignments.
However if enrolled participants subsequently developed exclusion criteria such as active alcohol or drug abuse, they were excluded from the study.